CAR T-cell products shine in real-world setting, reveal new insightsFebruary 18, 2021DLBCLLymphoma & Plasma Cell Disorders
How has the pandemic affected rural and urban cancer patients?February 18, 2021Patient & Survivor CareBreast CancerCNS/Brain CancerCOVID-19 UpdatesGastrointestinal CancerGenitourinary CancerGynecologic Cancer
Chronic GVHD therapies offer hope for treating refractory diseaseFebruary 17, 2021Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersDLBCL
Combo delivers ‘impressive’ survival results in first-line RCC settingFebruary 17, 2021Genitourinary CancerRenal Cell Carcinoma
Prognostic gene signature identifies high- vs. low-risk DLBCL patientsFebruary 17, 2021DLBCLLymphoma & Plasma Cell Disorders
One-third of health care workers leery of getting COVID-19 vaccine, survey showsFebruary 16, 2021COVID-19 Updates
Cabozantinib could be new standard for papillary RCCFebruary 16, 2021Genitourinary CancerRenal Cell Carcinoma
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseasesFebruary 16, 2021ImmunotherapyMelanomaGastroenterologyGastrointestinal Cancer
FDA approves first drug that protects against chemo-induced myelosuppressionFebruary 16, 2021Lung Cancer
